Oral levofloxacin in the treatment of community-acquired pneumonia.
Braz J Infect Dis
; 4(2): 61-6, 2000 Apr.
Article
en En
| MEDLINE
| ID: mdl-10795070
ABSTRACT
We evaluated the efficacy of oral levofloxacin (500mg/day for 7-21 days) in the treatment of 20 adults patients with community-acquired pneumonia (CAP) requiring hospitalization in an open prospective study. The microbiological cause of the pneumonia was identified in 14/20 patients using lower respiratory tract secretions obtained by bronchoscopy (12) and/or blood culture (2). Eight patients had S. pneumoniae, 2 P.aeruginosa, 1 H.influenzae, 1 S.aureus, 1 mixed S. aureus and K.pneumoniae, and 1 E.coli and Grp.D Streptococcus. All of the patients evaluated were judged to be improved or cured. Levofloxacin is an additional option as monotherapy for the treatment of CAP.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Ofloxacino
/
Infecciones Comunitarias Adquiridas
/
Neumonía Bacteriana
/
Levofloxacino
/
Antiinfecciosos
Tipo de estudio:
Etiology_studies
/
Observational_studies
Límite:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Braz J Infect Dis
Asunto de la revista:
DOENCAS TRANSMISSIVEIS
Año:
2000
Tipo del documento:
Article
País de afiliación:
Brasil